Janney Montgomery Scott Starts Recro Pharma (REPH) at Buy
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Janney Montgomery Scott initiated coverage on Recro Pharma (NASDAQ: REPH) with a Buy rating and a price target of $21.00.
Shares of Recro Pharma closed at $9.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
- Credit Suisse Starts Nutanix (NTNX) at Outperform
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesJanney Montgomery Scott
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!